Aminoglycoside formulation for aerosolization

Details Aminoglycoside formulation for aerosolization Aminoglycoside formulation for aerosolization

1994-10-19

1996-04-16

Raymond, Richard L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514956, A61K 912, A61K 3173

Patent

active

055082696

ABSTRACT:
An aminoglycoside formulation for delivery by aerosolization. The concentrated aminoglycoside formulation containing an efficacious amount of aminoglycoside able to inhibit 95-100% of susceptible bacteria. Aminoglycoside formulated in 5 ml solution of a quarter normal saline having pH between 5.5 and 6.5. The method for treatment of endobronchial infections by a produced by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 .mu., produced by a jet or ultrasonic nebulizer.

REFERENCES:
patent: 4424216 (1984-01-01), Cerami et al.
patent: 5006343 (1991-04-01), Benson et al.
Margaret E. Hodson, et al., Aerosol Carbenicillin and Gentamicin Treatment of Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis, The Lancet, pp. 1137-1139, Nov. 21, 1981.
David Stephens, et al., Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis, Pediatric Infectious Diseases, vol. 2, No. 3, pp. 209-211, May 1983.
Jack Levy, et al., Bioactivity of Gentamicin in Purulent Sputum from Patients with Cystic Fibrosis or Bronchiectasis: Comparison with Activity in Serum, The Journal of Infectious Diseases, vol. 148, No. 6, pp. 1069-1075, Dec. 1993.
Michael A. Wall, Inhaled Antibiotics in Cystic Fibrosis, The Lancet, Jun. 11, 1993.
Paul M. Mendelman, et al., Aminoglycoside Penetration, Inactivation, and Efficacy in Cystic Fibrosis Sputum.sup.1-3, Am. Rev. Respir. Diseases, 132:761-765, 1985.
P. Kun, et al., Nebulized gentamicin in children and adolescents with cystic fibrosis, Aust. Paediatr. J., 20:43-45, 1984.
Ian MacLusky, et al., Inhaled antibiotics in cystic fibrosis: Is there a therapeutic effect?, J. Pediatr., 108(2):861-865, 1986.
F. Carswell, et al. A Controlled Trial of Nebulized Aminoglycoside and Oral Flucloxacillin Versus Placebo in the Outpatient Management of Children with Cystic Fibrosis, Br. J. Dis. Chest, 81, 356-360, 1987.
S. P. Newman, et al., Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern, Thorax, 43:318-322, 1988.
Gratiana Steinkamp, et al., Long-term Tobramycin Aerosol Therapy in Cystic Fibrosis, Pediatric Pulmonary, 6:91-98, 1989.
Arnold L. Smith, et al., Safety of Aerosol Tobramycin for 3 Months to Patients with Cystic Fibrosis, Pediatric Pulmonary, 7:265-271, 1989.
Ian B. MacLusky, et al., Long-Term Effects of Inhaled Tobramycin in Patients with Cystic Fibrosis Colonized with Pseudomonas aeruginosa, Pediatric Pulmonology, 7:42-48, 1989.
Pulmonary Disorders Cystic Fibrosis (CF), The Merck Manual, 16th Edition, Chapter 196, pp. 2207-2211, 1992.
Bonnie W. Ramsey, Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis, New England Journal of Medicine, 328:1740-1746, Jun. 17, 1993.
Physicians' Desk Reference, 48th Edition, pp. 472-473, 914-917, 1250-1253, (1994).
Stephen G. Jenkins, Aerosolized Amikacin Administration to Cystic Fibrosis Patients Chronically Infected with Pseudomonas aeruginosa, p. 147, Presented at the 26th Annual Meeting of the Cystic Fibrosis Foundation, Anaheim, California, May 16-19, 1985. Abstract.
Ian Nathanson, et al., Effectiveness of Aerosolized Gentamicin in Cystic Fibrosis (CF), p. 145, Presented at the 26th Annual Meeting of the Cystic Fibrosis Foundation, Anaheim, California, May 16-19, 1985. Abstract.
Chun-I Wang, et al., The Effect of Tobramycin Aerosol to Pulmonary Infection from Pseudomonas aeruginosa in Patients with Cystic Fibrosis (CF), p. 159, Presented at the 25th Annual Meeting of the Cystic Fibrosis Foundation, San Jose, California, Apr. 27-30, 1984. Abstract.
Martha N. Franz, et al., Evaluation of Tobramycin Aerosol Therapy in Cystic Fibrosis (CF), p. 143, Presented at the 26th Annual Meeting of the Cystic Fibrosis Foundation, Anaheim, California, May 16-19, 1985. Abstract.

Affiliated with

Also associated with

Rating

Aminoglycoside formulation for aerosolization does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aminoglycoside formulation for aerosolization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoglycoside formulation for aerosolization will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-325237